CL2024002733A1 - Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos. - Google Patents
Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.Info
- Publication number
- CL2024002733A1 CL2024002733A1 CL2024002733A CL2024002733A CL2024002733A1 CL 2024002733 A1 CL2024002733 A1 CL 2024002733A1 CL 2024002733 A CL2024002733 A CL 2024002733A CL 2024002733 A CL2024002733 A CL 2024002733A CL 2024002733 A1 CL2024002733 A1 CL 2024002733A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- high doses
- ocular disorders
- vegf antagonists
- angiogenic ocular
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 230000002491 angiogenic effect Effects 0.000 title abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319869P | 2022-03-15 | 2022-03-15 | |
| US202263404512P | 2022-09-07 | 2022-09-07 | |
| US202263404893P | 2022-09-08 | 2022-09-08 | |
| US202263411594P | 2022-09-29 | 2022-09-29 | |
| US202263412165P | 2022-09-30 | 2022-09-30 | |
| US202263421298P | 2022-11-01 | 2022-11-01 | |
| US202263434920P | 2022-12-22 | 2022-12-22 | |
| US202363444480P | 2023-02-09 | 2023-02-09 | |
| US202363447582P | 2023-02-22 | 2023-02-22 | |
| CA3190733A CA3190733A1 (en) | 2022-03-15 | 2023-02-22 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002733A1 true CL2024002733A1 (es) | 2025-02-21 |
Family
ID=85704021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002733A CL2024002733A1 (es) | 2022-03-15 | 2024-09-11 | Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos. |
| CL2025001818A CL2025001818A1 (es) | 2022-03-15 | 2025-06-18 | Uso de aflibercept para tratar o prevenir degeneración macular neovascular relacionada con la edad. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025001818A CL2025001818A1 (es) | 2022-03-15 | 2025-06-18 | Uso de aflibercept para tratar o prevenir degeneración macular neovascular relacionada con la edad. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024420A1 (enExample) |
| EP (1) | EP4245312A1 (enExample) |
| JP (1) | JP2023135646A (enExample) |
| KR (1) | KR20230135013A (enExample) |
| CN (1) | CN119136823A (enExample) |
| AU (2) | AU2023233561A1 (enExample) |
| CA (1) | CA3253640A1 (enExample) |
| CL (2) | CL2024002733A1 (enExample) |
| IL (1) | IL315374A (enExample) |
| JO (1) | JOP20240202A1 (enExample) |
| MX (1) | MX2024011079A (enExample) |
| TW (1) | TW202400214A (enExample) |
| WO (1) | WO2023177691A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| WO2025217334A1 (en) * | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
| KR20260096819A (ko) * | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| IL318292A (en) | 2017-12-13 | 2025-03-01 | Regeneron Pharma | Devices and methods for administering precise doses |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020326243A1 (en) * | 2019-08-06 | 2022-02-17 | F. Hoffmann-La Roche Ag | Personalized treatment of ophthalmologic diseases |
| FI4185318T3 (fi) * | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
-
2023
- 2023-03-14 TW TW112109388A patent/TW202400214A/zh unknown
- 2023-03-14 IL IL315374A patent/IL315374A/en unknown
- 2023-03-14 CN CN202380025712.6A patent/CN119136823A/zh active Pending
- 2023-03-14 CA CA3253640A patent/CA3253640A1/en active Pending
- 2023-03-14 WO PCT/US2023/015225 patent/WO2023177691A1/en not_active Ceased
- 2023-03-14 AU AU2023233561A patent/AU2023233561A1/en active Pending
- 2023-03-14 JP JP2023039398A patent/JP2023135646A/ja active Pending
- 2023-03-14 US US18/121,499 patent/US20240024420A1/en active Pending
- 2023-03-15 AU AU2023201638A patent/AU2023201638A1/en active Pending
- 2023-03-15 KR KR1020230034231A patent/KR20230135013A/ko active Pending
- 2023-03-15 EP EP23162090.7A patent/EP4245312A1/en active Pending
-
2024
- 2024-09-09 JO JOJO/P/2024/0202A patent/JOP20240202A1/ar unknown
- 2024-09-10 MX MX2024011079A patent/MX2024011079A/es unknown
- 2024-09-11 CL CL2024002733A patent/CL2024002733A1/es unknown
-
2025
- 2025-06-18 CL CL2025001818A patent/CL2025001818A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023201638A1 (en) | 2023-10-05 |
| EP4245312A1 (en) | 2023-09-20 |
| TW202400214A (zh) | 2024-01-01 |
| IL315374A (en) | 2024-11-01 |
| JOP20240202A1 (ar) | 2024-09-09 |
| CL2025001818A1 (es) | 2025-10-03 |
| KR20230135013A (ko) | 2023-09-22 |
| US20240024420A1 (en) | 2024-01-25 |
| JP2023135646A (ja) | 2023-09-28 |
| CN119136823A (zh) | 2024-12-13 |
| MX2024011079A (es) | 2024-12-06 |
| CA3253640A1 (en) | 2023-09-21 |
| WO2023177691A1 (en) | 2023-09-21 |
| AU2023233561A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002718A1 (es) | Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos. | |
| MX2024011079A (es) | Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos | |
| PE20240922A1 (es) | Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos | |
| MX2021001439A (es) | Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio. | |
| CL2020002719A1 (es) | Moduladores de nlrp3 | |
| MX385368B (es) | Metodos para el tratamiento de trastornos del movimiento involuntario anormal. | |
| CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| MX2022013454A (es) | Moduladores de la actividad del complemento. | |
| CL2020001047A1 (es) | Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma. | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| UY35381A (es) | Pirrolotriazinas como inhibidores del canal del ion potasio | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| UY36629A (es) | Indazolonas como moduladores de la señalización de tnf | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| CL2020001140A1 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x. | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| MX2020012012A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| CO2024011399A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| IT201600103956A1 (it) | Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma | |
| CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| MX2021012512A (es) | Tratamiento para la migra?a. | |
| CO2020001792A2 (es) | Combinaciones farmacéuticas |